Vnitr Lek 2015, 61(3):207-208

Experiences with biosimilar drugs in therapy

Jaroslav Škvor
Dětská klinika UJEP a Masarykovy nemocnice, Krajská zdravotní a.s., Ústí nad Labem, přednosta prim. MUDr. Jaroslav Škvor, CSc.

Biosimilar drugs or drugs which are similar to reference biological drugs represent a new treatment option within the biological treatment. They are already the standard biotherapeutics option in some fields of medicine, in others as in diabetology, remain to be evaluated. The article presents the definition of biosimilar drugs and summarizes the therapeutic benefits and attitudes of agencies for drug control in the United States and Europe.

Keywords: biosimilar drugs; biotherapy; diabetology

Received: February 18, 2015; Accepted: February 25, 2015; Published: March 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Škvor J. Experiences with biosimilar drugs in therapy. Vnitr Lek. 2015;61(3):207-208.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Světová zdravotnická organizace. Expertní komise pro biologickou standardizaci. Pokyny pro hodnocení podobných bioterapeutických přípravků (Guidelines on Evaluation of Similar Biotherapeutic Products, SBP). Světová zdravotnická organizace. [Online] 23. října 2009. Dostupné z WWW: <http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf>.
    2. Owens DR, Landgraf W, Schmidt A et al. The emergence of biosimilar insulin preparations-a cause for concern? Diabetes Technol Ther 2012; 14(11): 989-996. Go to original source... Go to PubMed...
    3. Schellekens H, Moors E. Clinical comparability and European biosimilar regulations. Nat Biotechnol 2010; 28(1): 28-31. Go to original source... Go to PubMed...
    4. Heinemann L. Biosimilar Insulins. Expert Opin Biol Ther 2012; 12(8): 1009-1016. Go to original source... Go to PubMed...
    5. Heinemann L, Hompesch M. Biosimilar Insulins: Basic Considerations. J Diabetes Sci Technol 2014; 8(1): 6-13. Go to original source... Go to PubMed...
    6. DeVries JH, Gough SCL, Kiljanski J et al. Biosimilar insulins: a European perspective. Diabetes Obes Metab 2014. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12410>. Go to original source... Go to PubMed...
    7. Rotenstein LS, Ran N, Shiverset JP et al. Opportunities and Challenges for Biosimilars: What's on the Horizon in the Global Insulin Market? Clin Diabetes 2012; 30(4): 138-150. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.